-transparent.png){kind=logo}
Liposomes were prepared to incorporate large amounts of amphotericin B. BALB/c mice were challenged with Cryptococcus neoformans and given liposome-associated amphotericin B (AMBL) or amphotericin B-deoxycholate (AMBD) intravenously. Mice that were treated with AMBL survived longer and had lower tissue counts of cryptococci than mice treated with AMBD or untreated control mice. The reduced acute toxicity of AMBL permitted much larger doses of amphotericin B to be given than were possible with AMBD. AMBL is a novel vehicle of administration that reduces toxicity and concentrates the drug in the appropriate target organs.
Related Publications
J R Graybill, and
P C Craven, and
R L Taylor, and
D M Williams, and
W E Magee
June 1980,
Sabouraudia,
J R Graybill, and
P C Craven, and
R L Taylor, and
D M Williams, and
W E Magee
April 1984,
The Journal of infectious diseases,
J R Graybill, and
P C Craven, and
R L Taylor, and
D M Williams, and
W E Magee
December 1989,
Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
J R Graybill, and
P C Craven, and
R L Taylor, and
D M Williams, and
W E Magee
January 1959,
Canadian Medical Association journal,
J R Graybill, and
P C Craven, and
R L Taylor, and
D M Williams, and
W E Magee
August 1990,
The Tohoku journal of experimental medicine,
J R Graybill, and
P C Craven, and
R L Taylor, and
D M Williams, and
W E Magee
February 1978,
Antimicrobial agents and chemotherapy,
J R Graybill, and
P C Craven, and
R L Taylor, and
D M Williams, and
W E Magee
October 1991,
The Journal of antimicrobial chemotherapy,
J R Graybill, and
P C Craven, and
R L Taylor, and
D M Williams, and
W E Magee
November 2019,
CEN case reports,
J R Graybill, and
P C Craven, and
R L Taylor, and
D M Williams, and
W E Magee
December 1992,
Antimicrobial agents and chemotherapy,
J R Graybill, and
P C Craven, and
R L Taylor, and
D M Williams, and
W E Magee
July 1966,
Journal of the American Veterinary Medical Association,
